Metastatic hormone refractory prostate cancer – pipeline
1. You can also request for sample page of above
mention reports on sample@aarkstore.com
2. Pages : 104
PDF - $ 2000 | Site Licence - $ 4000 $ | Enterprise License - $
6000 |
20% Off on above 1000$ Reports
25% off on purchase of 2 reports and 30% on purchase of
3 or more reports.
Discount till 31st Dec. 2012.
3. Summary
Global Markets Direct’s, Metastatic Hormone Refractory Prostate Cancer -
Pipeline Review, H2 2012, provides an overview of the indication’s
therapeutic pipeline. This report provides information on the therapeutic
development for Metastatic Hormone Refractory Prostate Cancer, complete
with latest updates, and special features on late-stage and discontinued
projects. It also reviews key players involved in the therapeutic
development for Metastatic Hormone Refractory Prostate Cancer. Metastatic
Hormone Refractory Prostate Cancer - Pipeline Review, Half Year is built
using data and information sourced from Global Markets Direct’s
proprietary databases, Company/University websites, SEC filings, investor
presentations and featured press releases from company/university sites
and industry-specific third party sources, put together by Global Markets
Direct’s team.
Note*: Certain sections in the report may be removed or altered based on
the availability and relevance of data for the indicated disease.
4. Scope
- A snapshot of the global therapeutic scenario for Metastatic Hormone
Refractory Prostate Cancer.
- A review of the Metastatic Hormone Refractory Prostate Cancer products
under development by companies and universities/research institutes based on
information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from
discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined
therapeutics.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under
development for Metastatic Hormone Refractory Prostate Cancer.
- Identify emerging players with potentially strong product portfolio and design
effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most
promising pipeline.
5. Table of Contents :
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Metastatic Hormone Refractory Prostate Cancer Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Metastatic Hormone Refractory
Prostate Cancer 10
Metastatic Hormone Refractory Prostate Cancer Therapeutics under
Development by Companies 12
Metastatic Hormone Refractory Prostate Cancer Therapeutics under
Investigation by Universities/Institutes 14
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18……………………..
6. Please follow link if you want More Related
Reports :
Pipeline Review, H2 2012
http://www.aarkstore.com/search/viewresults.asp?search=Pipeline
Review, H2 2012&PubId=&pagenum=1
